Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

In Vitro Activities of Dalbavancin and Nine Comparator Agents against Anaerobic Gram-Positive Species and Corynebacteria

Ellie J. C. Goldstein, Diane M. Citron, C. Vreni Merriam, Yumi Warren, Kerin Tyrrell, Helen T. Fernandez
Ellie J. C. Goldstein
1R. M. Alden Research Laboratory, Santa Monica, California 90404
2University of California at Los Angeles School of Medicine, Los Angeles, California 90073
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: EJCGMD@aol.com
Diane M. Citron
1R. M. Alden Research Laboratory, Santa Monica, California 90404
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Vreni Merriam
1R. M. Alden Research Laboratory, Santa Monica, California 90404
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yumi Warren
1R. M. Alden Research Laboratory, Santa Monica, California 90404
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kerin Tyrrell
1R. M. Alden Research Laboratory, Santa Monica, California 90404
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen T. Fernandez
1R. M. Alden Research Laboratory, Santa Monica, California 90404
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.47.6.1968-1971.2003
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Dalbavancin is a novel semisynthetic glycopeptide with enhanced activity against gram-positive species. Its comparative in vitro activities and those of nine comparator agents, including daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin, against 290 recent gram-positive clinical isolates strains, as determined by the NCCLS agar dilution method, were studied. The MICs of dalbavancin at which 90% of various isolates tested were inhibited were as follows: Actinomyces spp., 0.5 μg/ml; Clostridium clostridioforme, 8 μg/ml; C. difficile, 0.25 μg/ml; C. innocuum, 0.25 μg/ml; C. perfringens, 0.125 μg/ml; C. ramosum, 1 μg/ml; Eubacterium spp., 1 μg/ml; Lactobacillus spp., >32 μg/ml, Propionibacterium spp., 0.5 μg/ml; and Peptostreptococcus spp., 0.25 μg/ml. Dalbavancin was 1 to 3 dilutions more active than vancomycin against most strains. Dalbavancin exhibited excellent activity against gram-positive strains tested and warrants clinical evaluation.

The development of resistance in gram-positive organisms, including Staphylococcus aureus strains that are resistant to both oxacillin and vancomycin (9), has accentuated the need for new antimicrobial agents. Dalbavancin (BI 397) is a novel semisynthetic amide derivative of the glycopeptide MDL 62,476 that has enhanced activity against aerobic gram-positive species (2, 4, 5). Due to its very long half-life (9 to 12 days), it is under investigation at a dosage interval of 1 week. Little has been published regarding its activity against either fastidious aerobic bacteria or anaerobes. In order to evaluate the potential efficacy of dalbavancin against this broad spectrum of isolates, we determined its comparative in vitro activity against 290 recent aerobic and anaerobic clinical isolates.

Strains were recently isolated from clinical specimens obtained from adult patients between 1996 and 2002 and were identified by standard criteria (6, 10). The strains were consecutive isolates, except when needed to make at least 10 isolates per species. Staphylococcus aureus ATCC 29213 and Eubacterium lentum ATCC 43055 were tested simultaneously with the appropriate plates and environments. The numbers and species of clinical isolates tested are given in Table 1.

The suppliers of standard laboratory powders were as follows: dalbavancin, Versicor, Inc. (King of Prussia, Pa.); vancomycin, Eli Lilly & Co. (Indianapolis, Ind.); linezolid and clindamycin, Pharmacia (Kalamazoo, Mich.); quinupristin-dalfopristin, Aventis Pharmaceuticals (Somerset, N.J.); imipenem, Merck & Co. (West Point, Pa.); piperacillin-tazobactam, Wyeth-Ayerst (Philadelphia, Pa.); and metronidazole, Searle (Skokie, Ill.).

Susceptibility testing was performed according to National Committee for Clinical Laboratory Standards (NCCLS) standards (7, 8) by using an agar dilution method with (i) Mueller-Hinton agar and an inoculum of 104 CFU per spot for corynebacteria or (ii) brucella agar supplemented with hemin, vitamin K1, and 5% laked sheep blood and an inoculum of 105 CFU per spot for anaerobic species. Daptomycin was supplemented with Ca2+ (50 mg/liter) as suggested by the manufacturer.

The results of the study are shown in Table 1. Overall, 263 of 290 (91%) of isolates tested were inhibited by ≤1 μg of dalbavancin/ml. Dalbavancin exhibited excellent in vitro activity against the gram-positive strains tested with the exception of several Lactobacillus species. Dalbavancin was typically 1 to 3 dilutions more active than vancomycin against most of the strains and fivefold more active against C. innocuum. Dalbavancin (MIC90 [MIC at which 90% of the isolates tested are inhibited], 8 μg/ml) was less active than vancomycin (MIC90, 1 μg/ml) against C. clostridioforme, a gram-negative-appearing species, but had MICs similar to those of daptomycin and linezolid. Against three strains of C. difficile for which the MICs of linezolid and quinupristin-dalfopristin were 8 μg/ml, dalbavancin had MICs of 0.125 to 0.25 μg/ml.

Dalbavancin inhibited all Corynebacterium species, including Corynebacteriumamycolatum and Corynebacteriumjeikeium, at ≤1 μg/ml (MIC90, 0.5 μg/ml). Vancomycin, linezolid, and quinupristin-dalfopristin had similar activities against corynebacteria; daptomycin was more active against Corynebacteriumamycolatum (MIC90, 0.06 μg/ml) but was markedly less active against other Corynebacterium spp. (MIC90, 8 μg/ml). Actinomyces israelii strains that were resistant to daptomycin and linezolid were susceptible to dalbavancin, which was two- to sixfold more active than vancomycin. Lactobacillus acidophilus and Lactobacillus casei strains that were resistant to vancomycin also required >32 μg of dalbavancin/ml for inhibition. One strain of Lactobacillus oris required 4 μg of dalbavancin/ml for inhibition. One strain of Eubacterium saburreum required 2 μg of dalbavancin/ml for inhibition. Overall, 263 of 290 (91%) of isolates tested were inhibited by doses of ≤1 μg of dalbavancin/ml.

Dalbavancin demonstrated potent activity (<1 μg/ml) against a broad spectrum of gram-positive anaerobes and fastidious aerobes including Actinomyces species, Propionibacterium spp., Peptostreptococcus spp., and Clostridium species, including Clostridiumperfringens and Clostridiumdifficile but excluding Clostridiumclostridioforme. Dalbavancin was typically 1 to 3 dilutions more active than vancomycin against most of the strains, and fivefold more active against Clostridiuminnocuum. Dalbavancin was less active than vancomycin against Clostridiumclostridioforme, a gram-negative-appearing species, but had MICs similar to those of daptomycin and linezolid. Dalbavancin had MICs of 0.125 to 0.25 μg/ml against three strains of Clostridiumdifficile with linezolid and quinupristin-dalfopristin MICs of 8 μg/ml. Its overall activity compared favorably with that of the other agents tested.

Lactobacilli have been associated with vaginal health, whereas depletion has been associated with an increased risk of urinary tract infections and bacterial vaginosis (1, 11). Many patients self-medicate and take probiotic products containing Lactobacillus acidophilus whenever placed on antimicrobial agents. Glycopeptides have variable activity against Lactobacillus species; this appears to be due to the pentapeptide structure in nascent cell wall peptidoglycan (3). Goldstein et al. (4) reported on the activity of MDL 63,246, a precursor to dalbavancin, against a very limited number of Lactobacillus strains and found it to be active against Lactobacillusacidophilus, whereas Lactobacilluscasei, Lactobacillus fermentans, and Lactobacillusplantarum required higher concentrations for inhibition. In the present study, dalbavancin had limited activity (MICs ≥ 32 μg/ml) against Lactobacillus acidophilus and Lactobacilluscasei but was active against Lactobacillusfermentans (MICs ≤ 0.25 μg/ml); this finding could be viewed as a positive health factor allowing maintenance of the normal vaginal flora. Its activity against other Lactobacillus spp., such as Lactobacilluscatenaforme, Lactobacillusfermentans, and Lactobacillusplantarum, showed inhibition at ≤1 μg/ml and, given appropriate pharmacokinetics, might allow its use in the therapy of infections caused by those species.

The activity of dalbavancin against our corynebacteria isolates was generally equivalent to that of vancomycin. Dalbavancin inhibited all Corynebacterium spp., including Corynebacteriumamycolatum and Corynebacterium jeikeium, at ≤1 μg/ml (MIC90 = 0.5 μg/ml). Linezolid and quinupristin-dalfopristin also had similar activities. In a previous study (3), the dalbavancin MIC range for a smaller number of Corynebacterium isolates was found to be <0.03 to 0.13 μg/ml. These differences may be due to actual differences in activity against various strains or species or to the different methodologies used (agar dilution in the present study versus broth microdilution in the earlier study).

In conclusion, dalbavancin exhibited excellent in vitro activity against most of the gram-positive strains tested, with 263 of 290 (91%) of isolates inhibited by ≤1 μg/ml. Dalbavancin warrants clinical evaluation against infections caused by anaerobic gram-positive bacteria and corynebacteria.

View this table:
  • View inline
  • View popup
TABLE 1.

Comparative in vitro activities of dalbavancin against anaerobic gram-positive bacteria and corynebacteria

FOOTNOTES

    • Received 17 October 2002.
    • Returned for modification 21 February 2003.
    • Accepted 10 March 2003.
  • Copyright © 2003 American Society for Microbiology

REFERENCES

  1. 1.↵
    Cadieux, P., J. Burton, A. W. Bruce, C. Y. Kang, and G. Reid. 2002. Lactobacillus strains and vaginal ecology. JAMA287:1940-1941.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Candiani, G., M. Abbondi, M. Borgonovi, G. Rpmano, and F. Parenti. 1999. In vitro and in vivo antibacterial activity of BI 397, a new semisynthetic glycopeptide antibiotic. J. Antimicrob. Chemother.44:179-192.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    Ferain, T., J. N. Hobbs, Jr., J. Richardson, N. Bernard, D. Garymn, P. Hols, N. E. Allen, and J. Delcour. 1996. Knockout of the two ldh genes has major impact on peptidoglycan precursor synthesis in Lactobacillus plantarum. J. Bacteriol.178:5431-5437.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    Goldstein, B. P., G. Candiani, T. M. Arain, G. Romano, I. Ciciliato, M. Bereti, M. Abbondi, R. Scotti, M. Mainini, F. Ripamonti, A. Resconi, and M. Debnaro. 1995. Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic. Antimicrob. Agents Chemother.39:1580-1588.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Jones, R. N., D. J. Biedenbach, D. M. Johnson, and M. A. Pfaller. 2001. In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. J. Chemother.13:244-254.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    Murray, P. R., E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken. 1999. Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C.
  7. 7.↵
    National Committee for Clinical Laboratory Standards. 2001. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 5th ed. Approved standard M11-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  8. 8.↵
    National Committee for Clinical Laboratory Standards. 2000. Method for dilution antimicrobial susceptibility testing for bacteria that grow aerobically, 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  9. 9.↵
    Sievert, D. M., M. L. Boulton, G. Stoltman, D. Johnson, M. G. Stobierski, F. P. Downes, P. A. Somsel, J. Y. Rudnick, W. Brown, W. Hafeez, T. Lundstrom, E. Flanagan, J. Mitchell, and S. Chang. 2002. Staphylococcus aureus resistant to vancomycin-United States, 2002. Morb. Mortal. Wkly. Rep.51:565-567.
    OpenUrlPubMed
  10. 10.↵
    Summanen, P., E. J. Baron, D. M. Citron, C. A. Strong, H. M. Wexler, and S. M. Finegold. 1993. Wadsworth anaerobic bacteriology manual, 5th ed. Star Publishing Co., Belmont, Calif.
  11. 11.↵
    Weeks, J. C., H. Nelson, S. Gelber, D. Sargent, and G. Schroeder. 2002. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy versus open colectomy for colon cancer: a randomized trial. JAMA287:321-328.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
In Vitro Activities of Dalbavancin and Nine Comparator Agents against Anaerobic Gram-Positive Species and Corynebacteria
Ellie J. C. Goldstein, Diane M. Citron, C. Vreni Merriam, Yumi Warren, Kerin Tyrrell, Helen T. Fernandez
Antimicrobial Agents and Chemotherapy Jun 2003, 47 (6) 1968-1971; DOI: 10.1128/AAC.47.6.1968-1971.2003

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro Activities of Dalbavancin and Nine Comparator Agents against Anaerobic Gram-Positive Species and Corynebacteria
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vitro Activities of Dalbavancin and Nine Comparator Agents against Anaerobic Gram-Positive Species and Corynebacteria
Ellie J. C. Goldstein, Diane M. Citron, C. Vreni Merriam, Yumi Warren, Kerin Tyrrell, Helen T. Fernandez
Antimicrobial Agents and Chemotherapy Jun 2003, 47 (6) 1968-1971; DOI: 10.1128/AAC.47.6.1968-1971.2003
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
Bacteria, Anaerobic
glycopeptides
Gram-positive bacteria

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596